About Transmembrane protein 39A
Transmembrane protein 39A (TMEM39A) is a protein
from Homo sapiens identified by UniProt accession
Q9NV64, 488 residues long.
MolForge cross-references it against 0 known binders and
35 disease associations.
Target properties
| Protein name | Transmembrane protein 39A |
| UniProt accession | Q9NV64 |
| Gene | TMEM39A |
| Organism | Homo sapiens |
| Length | 488 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (35)
Diseases linked to this target (Open Targets).
- body height · score 0.21
- systemic lupus erythematosus · score 0.18
- primary biliary cirrhosis · score 0.16
- celiac disease · score 0.15
- lymphocyte count · score 0.14
- systemic scleroderma · score 0.14
- autoimmune disease · score 0.12
- blood protein measurement · score 0.10
- Thyroid preparation use measurement · score 0.09
- autoimmune thyroid disease · score 0.08
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NV64-F1 | alphafold | PREDICTED | 73.52 | — |
Amino-acid sequence (488 residues)
MPGGRRGPSR QQLSRSALPS LQTLVGGGCG NGTGLRNRNG SAIGLPVPPI TALITPGPVR HCQIPDLPVD GSLLFEFLFF IYLLVALFIQ YINIYKTVWW YPYNHPASCT SLNFHLIDYH LAAFITVMLA RRLVWALISE ATKAGAASMI HYMVLISARL VLLTLCGWVL CWTLVNLFRS HSVLNLLFLG YPFGVYVPLC CFHQDSRAHL LLTDYNYVVQ HEAVEESAST VGGLAKSKDF LSLLLESLKE QFNNATPIPT HSCPLSPDLI RNEVECLKAD FNHRIKEVLF NSLFSAYYVA FLPLCFVKST QYYDMRWSCE HLIMVWINAF VMLTTQLLPS KYCDLLHKSA AHLGKWQKLE HGSYSNAPQH IWSENTIWPQ GVLVRHSRCL YRAMGPYNVA VPSDVSHARF YFLFHRPLRL LNLLILIEGS VVFYQLYSLL RSEKWNHTLS MALILFCNYY VLFKLLRDRI VLGRAYSYPL NSYELKAN
Explore Transmembrane protein 39A with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets